Evaxion Biotech A/S — Existing cash and cash equivalents are expected to be sufficient to fund operating expenses and capital expenditure requirements for the first quarter of 2025
Evaxion Biotech A/S——预计现有的现金和现金等价物将足以为2025年第一季度的运营支出和资本支出需求提供资金
Evaxion Biotech A/S — Existing cash and cash equivalents are expected to be sufficient to fund operating expenses and capital expenditure requirements for the first quarter of 2025
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.